(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/03914 A3

(51) International Patent Classification[7]: A61K 31/195

(21) International Application Number: PCT/US01/21422

(22) International Filing Date: 6 July 2001 (06.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/216,275 6 July 2000 (06.07.2000) US

(71) Applicant *(for all designated States except US)*: **DELSYS PHARMACEUTICAL CORPORATION** [US/US]; 11 Deer Park Drive, Suite 202, Monmouth Junction, NJ 08852 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MURARI, Ramaswamy** [US/US]; 39 Wesley Road, Hillsborough, NJ 08876 (US). **CHRAI, Suggy, S.** [US/US]; 16 Bodine Drive, Cranbury, NJ 08512 (US).

(74) Agent: **JACKSON, Arthur, E.**; Dechert, Princeton Pike Corporate Center, 997 Lenox Drive, Building 3, Suite 210, Lawrenceville, NJ 08648 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
6 June 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/03914 A3

162162

(54) Title: IMPROVED THYROID HORMONE FORMULATIONS

(57) Abstract: A method is disclosed for formulating a solid dosage of thyroid hormone, while avoiding instability caused by interaction of the active ingredient with excipients. The thyroid hormone may be levothyroxine sodium or triiodothyronine. The method comprises depositing the active ingredient, preferably electrostatically, as a dry powder substantially free of excipients, onto a pharmaceutically acceptable polymer substrate. Solid pharmaceutical dosage forms also are disclosed.